Ventrus Biosciences Interest Expense:
0.00 for Dec. 31, 2012Ventrus Biosciences Historical Interest Expense Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 0.00 |
| Sept. 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| Dec. 31, 2011 | 0.00 |
| Sept. 30, 2011 | 0.0306M |
| June 30, 2011 | 0.0414M |
| March 31, 2011 | 0.0447M |
| Dec. 31, 2010 | 0.223M |
| Sept. 30, 2010 | 0.6861M |
| June 30, 2010 | 0.6845M |
| March 31, 2010 | 1.57M |
| Dec. 31, 2009 | 0.5613M |
| Sept. 30, 2009 | 0.2227M |
| June 30, 2009 | 0.2012M |
| March 31, 2009 | 0.2142M |
About Interest Expense
When companies borrow money to expand or maintain their business operations, they must pay interest on the money that they borrow. The interest expense is the annual accrued amount of interest that the company paid (or sometimes will have to pay) to its creditors.
A higher interest expense means that the company is paying more to its debtors. In general, a company's capital structure with a heavier debt focus will have higher interest expenses. Liquidity ratios such as EBIT/Interest Expense can help investors see if increasing Interest Expenses are problematic.
YCharts includes both operating interest expense and non-operating interest expense in our numbers.
Learn More
VTUS Interest Expense Benchmarks
| Companies | |
|---|---|
| GlaxoSmithKline | 308.51M |
| Tetraphase Pharmaceuticals | 0.407M |
| Zoetis | 22.00M |
VTUS Interest Expense Rankings
| Overall |
99th percentile 50 of 8002 |
| Sector |
98th percentile 9 of 684 in Healthcare |
| Industry |
98th percentile 1 of 54 in Drug Manufacturers - Major |
VTUS Interest Expense Range, Past 5 Years
| Minimum | 0.00 | Dec 2011 |
| Maximum | 1.570M | Mar 2010 |
| Average | 0.2800M |
